SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, today ...
LivaNova has published 12-month data supporting its proximal hypoglossal nerve stimulation (pHGNS) system for sleep apnea.
11d
ProSomnus Sleep Technologies, Inc.: ProSomnus Receives FDA Class II Clearance for RPMO2 OSA Device
ProSomnus Sleep Technologies ("the Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine, today ...
RMD's growth strategy, rising device demand and solid finances support momentum, but macro pressures and stiff competition could test its outlook.
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal ...
Medical Device Network on MSN
ProSomnus secures FDA clearance for RPMO2 device
RPMO₂ features a fully embedded oximeter over maxillary dentition, using buccal vestibule mucosa behind the upper lip.
SnoreRX examines its FDA-cleared mandibular advancement mouthpiece design, 1-millimeter adjustable calibration, boil-and-bite ...
The latest type 2 diabetes (T2D) management guidance from the American Association of Clinical Endocrinology (AACE) covers ...
Could you provide an overview of the Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment (DUET) ...
An Excel-based actuarial model (1 million lives; 49% eligible; 10% treated) estimated semaglutide coverage could be ...
Weight-loss drugs, finding use in wellness and weddings alike, promise a booster shot for India’s generics giants. It needs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results